Discovery of 6α-Thiazolylcarboxamidonaltrexamine Derivative (NTZ) as a Potent and Central Nervous System Penetrant Opioid Receptor Modulator with Drug-like Properties for Potential Treatment of Opioid Use Disorder
Open Access
- 5 December 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (12) , 4165-4182
Abstract
The development of highly potent and selective μ opioid receptor (MOR) modulators with favorable drug-like properties has always been a focus in the opioid domain. Our previous efforts led to the discovery of a lead compound designated as NAT, a potent centrally acting MOR modulator. However, the fact that NAT precipitated considerable withdrawal effects at higher doses largely impaired its further development. In the light of the concept of activity cliff and CNS multiparameter optimization algorithm, a nitrogen atom was incorporated into the thiophene ring of NAT, aiming to preserve desirable pharmacological activities and CNS permeability while alleviating withdrawal symptoms. Among all 16 new analogs, compound 6 (NTZ) exhibited improved opioid receptor selectivity, enhanced in vivo antagonistic effect, and overall fewer withdrawal symptoms compared to NAT. Further assessment of several key drug-like properties suggested a favorable ADMET profile of NTZ. Taken together, NTZ shows promise as a potential lead to treat opioid use disorder.Keywords
Funding Information
- National Institute on Drug Abuse (DA024022, DA044855, DA050311, P30DA033934)
This publication has 70 references indexed in Scilit:
- Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeysPsychopharmacology, 2020
- Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USANeurotherapeutics, 2020
- Drug–Drug Interactions of a Novel κ-Opioid Receptor Agonist, Nalfurafine Hydrochloride, Involving the P-GlycoproteinEuropean Journal of Drug Metabolism and Pharmacokinetics, 2015
- Methods of Detoxification and Their Role in Treating Patients With Opioid DependenceJAMA, 2005
- Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein bindingJournal of Pharmaceutical Sciences, 2003
- Microtiter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450Analytical Biochemistry, 1997
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997
- The index of radiographic area (IRA): a new approach to estimating the severity of vertebral deformityBone and Mineral, 1991
- Revised methods for the Salmonella mutagenicity testMutation Research/Environmental Mutagenesis and Related Subjects, 1983
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973